MedTrace Logo

Olmesartan on Ambulatory Blood Pressure Change

NCT00854763 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-03-03

No results posted yet for this study

Summary

We will conduct an open label, non-comparative, observational study to evaluate the efficacy, safety and tolerability of Olmesartan therapy in Taiwan patients with essential hypertension, and the primary objective is the change in the 24-hour mean systolic blood pressure from baseline to the day after post-treatment week-12 visit according to the ambulatory blood pressure monitoring.

Conditions

Interventions

DRUG

olmesartan

olmesartan

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Kuo-Liong Chien, MD, PhD · Institute of Preventive Medicine, College of Public Health, National Taiwan University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00854763 on ClinicalTrials.gov